392 related articles for article (PubMed ID: 34887874)
21. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
[TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
Front Immunol; 2022; 13():819080. PubMed ID: 35359993
[TBL] [Abstract][Full Text] [Related]
23. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
24. One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.
Ouyang X; Gong Y
Front Immunol; 2022; 13():912526. PubMed ID: 35720276
[TBL] [Abstract][Full Text] [Related]
25. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
[TBL] [Abstract][Full Text] [Related]
26. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
27. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
29. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
Front Oncol; 2021; 11():714267. PubMed ID: 34604051
[TBL] [Abstract][Full Text] [Related]
30. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
31. m6A regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in patients with intracranial aneurysms.
Maimaiti A; Turhon M; Cheng X; Su R; Kadeer K; Axier A; Ailaiti D; Aili Y; Abudusalamu R; Kuerban A; Wang Z; Aisha M
Front Neurol; 2022; 13():889141. PubMed ID: 35989938
[TBL] [Abstract][Full Text] [Related]
32. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
33. Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia.
Yuan S; Cong Z; Ji J; Zhu L; Jiang Q; Zhou Y; Shen Q; Damiani D; Xu X; Li B
Ann Transl Med; 2022 Aug; 10(16):902. PubMed ID: 36111007
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
35. The N6-methyladenosine RNA modification in acute myeloid leukemia.
Yankova E; Aspris D; Tzelepis K
Curr Opin Hematol; 2021 Mar; 28(2):80-85. PubMed ID: 33337619
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of m
Liu T; Li H; Du G; Ma J; Shen J; Zhao H; Luo F; Li H
Gene; 2022 May; 821():146250. PubMed ID: 35151825
[TBL] [Abstract][Full Text] [Related]
37. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
38. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
Chen M; Wong CM
Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
[TBL] [Abstract][Full Text] [Related]
39. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
40. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
